Biogen Inc.
BIIB
NASDAQ·Healthcare·Drug Manufacturers - General·Mkt cap $32.6B
$220.83
▼ -1.64%
P/E
1.47
Mkt Cap
$32.6B
52-Wk Range
$135.39–$225.80
52-Week Range
$135.39 - $225.80
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 56.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Advanced neurological research capabilities
- Extensive proprietary drug development pipeline
- Strong intellectual property portfolio
- Strategic research collaborations
Bear Case
2 risks
- Low volatility (beta 0.2).
- Premium valuation to Large Cap Pharma peers
Growth
Stable outlook
Expansion of Alzheimer's treatment market
Value
Premium valuation to Large Cap Pharma peers
Momentum
Strong
+14.7% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying BIIB right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 29, 2026
Reported EPS of $3.60 vs $2.94 consensus (+22.4% surprise). Revenue of $2.7B vs $2.5B expected (+11.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+22.4%
Revenue trend · last 8Q
—
+3%
+6%
+7%
-0%
-7%
+2%
+3%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.5B
$2.5B
$2.4B
$2.6B
$2.5B
$2.3B
$2.5B
$2.7B
Margins · last 8Q
Gross
-66.4%
Operating
-14.5%
Profit
3.6%
Wall Street consensus
18 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
28%
Sell
6%
Median Price Target
—
Latest: Piper Sandler · Sep 3, 2026
vs Industry
How BIIB stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related